Federal contract award
75N93019C00053
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $78.2M |
| Current contract value | $78.2M |
| Potential contract value / ceiling | $141.3M |
| Start date | Aug 26, 2019 |
| Current end date | Sep 15, 2028 |
| Potential end date | Sep 15, 2028 |
| Latest award activity | Sep 22, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 33 of 33 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 22, 2025 | P00032 | $-827.4K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Sep 4, 2025 | P00031 | $1.1M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Jul 7, 2025 | P00030 | $529.2K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Mar 4, 2025 | P00029 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Nov 4, 2024 | P00028 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Sep 20, 2024 | P00027 | $-1.1M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Aug 26, 2024 | P00026 | $3.7M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Jul 1, 2024 | P00025 | $7.1M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Mar 15, 2024 | P00024 | $312.6K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Jan 3, 2024 | P00023 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Nov 16, 2023 | P00022 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Sep 12, 2023 | P00021 | $9.2M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Mar 21, 2023 | P00020 | $889.4K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Feb 23, 2023 | P00019 | $1.8M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Jan 22, 2023 | P00018 | $482.1K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Dec 15, 2022 | P00017 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Sep 12, 2022 | P00016 | $672.5K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Aug 9, 2022 | P00015 | $6.5M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. |
| Jul 12, 2022 | P00014 | $321.8K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. . |
| May 27, 2022 | P00013 | $634.4K | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 30.A-B AND EXTEND THE PERIOD OF PERFORMANCE OF OPTION 34. |
| Mar 22, 2022 | P00012 | $1.0M | 19C00053 COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO ADD FUNDS TO AND EXTEND THE PERIOD OF PERFORMANCE OF OPTION 8. |
| Feb 9, 2022 | P00011 | $0 | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE OF OPTIONS 17.A AND 17.B, AND INCORPORATE IPP HHSAR |
| Dec 23, 2021 | P00010 | $4.0M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 23, EXERCISE OPTION 39 WITH AN EQUITABLE ADJUSTMENT, AND UPDATE VARI |
| Oct 12, 2021 | P00009 | $0 | EO14042 19C00053 COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO ADD FAR DEVIATION CLAUSE 52.223-99 ENSURING ADEQUATE COVID-19 |
| Aug 9, 2021 | P00008 | $1.9M | 19C00053; COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE. THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE SEVERABLE OPTION 2 AND NON-SEVERABLE OPTIONS 27.A AND 34 AND UPDATE VARIOUS |
| May 25, 2021 | P00007 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIODS OF PERFORMANCE OF OPTION 26.A AND OPTION 33 AND UPDATE VARIOUS ARTICLES AND CLAUSES. |
| Apr 26, 2021 | P00006 | $4.0M | THE PURPOSE OF THIS MODIFICATION IS TO ADD FUNDS TO OPTION 8 AND UPDATE VARIOUS ARTICLES AND CLAUSES. |
| Feb 23, 2021 | P00005 | $1.3M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTIONS 17.A AND 17.B, UPDATE KEY PERSONNEL, AND UPDATE VARIOUS ARTICLES AND CLAUSES |
| Sep 3, 2020 | P00004 | $11.9M | THE PURPOSE OF THIS MODIFICATION IS TO REVISE CLAUSES IN ACCORDANCE WITH INTERIM FAR RULE 2019-009, EFFECTIVE AUGUST 13, 2020, CORRECT LINE ITEM NUMBERS AND REPLACE THE PERIOD OF PERFORMANCE WITH THE EXECUTIVE LEVEL II SALARY RATE LIMITATIONS IN ARTI |
| Aug 7, 2020 | P00003 | $7.2M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 9 AND UPDATE VARIOUS ARTICLES AND CLAUSES. |
| Jun 1, 2020 | P00002 | $1.8M | THE PURPOSE OF THIS MODIFICATION IS TO RESERVE OPTION 14, ADD OPTIONS 26-39, EXERCISE OPTIONS 1, 26.A, AND 33, UPDATE THE KEY PERSONNEL AND STATEMENT OF WORK, AND UPDATE VARIOUS ARTICLES AND CLAUSES. |
| Sep 6, 2019 | P00001 | $0 | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE |
| Aug 26, 2019 | 0 | $13.8M | COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) COMPONENT B: VACCINE MANUFACTURING AND TOXICOLOGY CORE |
Estimated positioning window
Sep 15, 2027 – Mar 15, 2028
Recompete signal: . Rule-based research score; positioning dates are estimates.
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-09-15 (684 days from calculation)
- +25 points
- 103 historical awards in this buyer and category group
- +15 points
- 33 recorded award transactions
- +10 points
- Latest award action: 2025-09-22
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.